Gary J. Speier

Carlson Caspers represents Teva in an Inter Partes Review (IPR) concerning Teva’s Paragraph IV ANDA challenge of 1 patent covering the active pharmaceutical ingredient (API) present in the drug saxagliptin hydrochloride (Onglyza®), compositions containing the API, and methods of using the API. The IPR [IPR2016-01122] was filed during the related Hatch-Waxman patent litigation and is currently pending.